In this new age, Clinical research is experiencing a soft but mighty revolution, powered by the introduction of open-source ...

NEW YORK, NY, UNITED STATES, May 29, 2025 /EINPresswire.com/ -- CCRPS, internationally recognized as a leader in clinical ...

Magic mushrooms” may conjure images of people in the 1960s using hallucinogenic drugs to launch journeys of self-discovery.

NeuroPace Inc. (NASDAQ:NPCE) saw its stock nosedive by 36.1% today after announcing that its NAUTILUS clinical trial failed ...

Contemporary Clinical trials, 33: 5-11 (2012) Zheng Su, PhD, is Senior Statistical Scientist at Genentech Inc. and Editor-in-Chief of Contemporary Clinical Trials, which provides a platform for ...

After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in ...

No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in ...

NeuroPace has reported the initial primary endpoint one-year outcomes from the NAUTILUS trial of the RNS System.

Across Harvard’s schools, researchers described a wave of destruction following sweeping terminations of federally funded ...

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

A research team from the Germans Trias i Pujol Research Institute (IGTP), has published a study in the journal Scientific ...